RESHAPE LIFESCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.188 USD | +4.44% |
|
+6.70% | -24.71% |
| May. 15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M | MT |
Financials (USD)
| Sales 2024 * | 9.99M | Sales 2025 * | 11.99M | Capitalization | 4.41M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -5M | EV / Sales 2024 * | 0.44 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.37 x |
| P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.52
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on ReShape Lifesciences Inc.
More recommendations
More press releases
| 1 day | +4.44% | ||
| 1 week | +6.70% | ||
| Current month | +13.25% | ||
| 1 month | +11.84% | ||
| 3 months | +22.08% | ||
| 6 months | -16.37% | ||
| Current year | -24.71% |
1 week
0.17
0.23
1 month
0.160.23
Current year
0.140.30
1 year
0.142.59
3 years
0.14475.00
5 years
0.14720.00
10 years
0.141 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
| Director of Finance/CFO | 63 | 21-06-14 | |
Dov Gal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 15-12-31 |
Dan Gladney
CHM | Chairman | 70 | 15-10-31 |
| Director/Board Member | 70 | 21-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.188 | +4.44% | 512,464 |
| 24-05-23 | 0.18 | +0.73% | 730,035 |
| 24-05-22 | 0.1787 | -3.51% | 774,601 |
| 24-05-21 | 0.1852 | -12.17% | 1,904,353 |
| 24-05-20 | 0.2109 | +19.67% | 6,084,055 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.188
USD
Average target price
1
USD
Spread / Average Target
+431.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.71% | 4.41M | |
| +10.03% | 223B | |
| +13.59% | 195B | |
| +20.01% | 144B | |
| +30.83% | 111B | |
| +2.05% | 65.01B | |
| +15.38% | 53.02B | |
| +3.96% | 50.45B | |
| +8.37% | 44.15B | |
| +3.27% | 36.45B |
- Stock Market
- Equities
- RSLS Stock
